FindTrial
Sign In

T3011

BIOLOGICAL8 trials

Sponsors

ImmVira Pharma Co. Ltd, West China Hospital, Shanghai Pharmaceuticals Holding Co., Ltd

Conditions

Advanced Colorectal CancerAdvanced MelanomaAdvanced Solid TumorBreast CancerColorectal CancerEndometrial CancerEsophagus CancerHNSCC

Phase 1

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RecruitingNCT04370587
ImmVira Pharma Co. LtdHNSCC, Melanoma, NSCLC +3
Start: 2020-09-17End: 2027-01-10Target: 30Updated: 2025-10-08
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
Active, not recruitingNCT04780217
ImmVira Pharma Co. LtdColorectal Cancer, Endometrial Cancer, Hepatocellular Carcinoma +3
Start: 2021-08-10End: 2025-08-31Target: 42Updated: 2024-03-04
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
NCT05598268
ImmVira Pharma Co. LtdAdvanced Solid Tumor, Liver Cancer, Lung Cancer +2
Start: 2022-03-01End: 2024-12-31Target: 74Updated: 2022-10-28
A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
NCT05602792
ImmVira Pharma Co. LtdAdvanced Solid Tumor, Breast Cancer, Esophagus Cancer +4
Start: 2020-04-21End: 2024-01-31Target: 233Updated: 2022-11-02
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
NCT06200363
West China HospitalAdvanced Colorectal Cancer
Start: 2023-09-21End: 2024-11-30Target: 15Updated: 2024-01-11
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
NCT06200376
West China HospitalMalignant Ascites
Start: 2023-09-28End: 2024-12-31Target: 10Updated: 2024-01-11
A Clinical Study of T3011 in Subjects With Advanced Melanoma
RecruitingNCT06214156
Shanghai Pharmaceuticals Holding Co., LtdAdvanced Melanoma
Start: 2024-01-26End: 2026-09-30Target: 42Updated: 2026-08-06

Phase 2

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
RecruitingNCT06971614
ImmVira Pharma Co. LtdNonmuscle-invasive Bladder Cancer
Start: 2025-06-09End: 2029-05-31Target: 160Updated: 2026-08-18

Related Papers

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC
BMC Medicine2026-02-20
Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies.
Journal of Clinical Oncology2024-06-011 citations
A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.
Journal of Clinical Oncology2023-06-0114 citations
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
Journal of Clinical Oncology2023-06-016 citations
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.
Journal of Clinical Oncology2023-06-01
Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study.
Journal of Clinical Oncology2023-06-01
A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.
Journal of Clinical Oncology2021-05-206 citations